CN108368143B - 用于癌症疗法的单马来酰亚胺官能化的铂化合物 - Google Patents

用于癌症疗法的单马来酰亚胺官能化的铂化合物 Download PDF

Info

Publication number
CN108368143B
CN108368143B CN201680072428.4A CN201680072428A CN108368143B CN 108368143 B CN108368143 B CN 108368143B CN 201680072428 A CN201680072428 A CN 201680072428A CN 108368143 B CN108368143 B CN 108368143B
Authority
CN
China
Prior art keywords
cancer
alkyl
compound
alkylene
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680072428.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN108368143A (zh
Inventor
C·科沃尔
P·赫费特
W·伯格
B·K·开普勒
J·迈尔
V·皮希勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medizinische Universitaet Wien
Universitaet Wien
Original Assignee
Medizinische Universitaet Wien
Universitaet Wien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Universitaet Wien, Universitaet Wien filed Critical Medizinische Universitaet Wien
Publication of CN108368143A publication Critical patent/CN108368143A/zh
Application granted granted Critical
Publication of CN108368143B publication Critical patent/CN108368143B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680072428.4A 2015-12-09 2016-12-09 用于癌症疗法的单马来酰亚胺官能化的铂化合物 Expired - Fee Related CN108368143B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15198739.3 2015-12-09
EP15198739 2015-12-09
PCT/EP2016/080453 WO2017097986A1 (en) 2015-12-09 2016-12-09 Monomaleimide-functionalized platinum compounds for cancer therapy

Publications (2)

Publication Number Publication Date
CN108368143A CN108368143A (zh) 2018-08-03
CN108368143B true CN108368143B (zh) 2022-02-01

Family

ID=54849106

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680072428.4A Expired - Fee Related CN108368143B (zh) 2015-12-09 2016-12-09 用于癌症疗法的单马来酰亚胺官能化的铂化合物

Country Status (21)

Country Link
US (2) US10723748B2 (https=)
EP (1) EP3386997B1 (https=)
JP (1) JP6867652B2 (https=)
CN (1) CN108368143B (https=)
AU (1) AU2016367306B2 (https=)
CA (1) CA3004630A1 (https=)
CY (1) CY1124529T1 (https=)
DK (1) DK3386997T3 (https=)
ES (1) ES2898704T3 (https=)
HR (1) HRP20211466T1 (https=)
HU (1) HUE056897T2 (https=)
IL (1) IL259864B (https=)
LT (1) LT3386997T (https=)
MX (1) MX377528B (https=)
PL (1) PL3386997T3 (https=)
PT (1) PT3386997T (https=)
RS (1) RS62412B1 (https=)
SG (1) SG11201804885TA (https=)
SI (1) SI3386997T1 (https=)
SM (1) SMT202100709T1 (https=)
WO (1) WO2017097986A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3797768A1 (en) * 2014-06-23 2021-03-31 Placon Therapeutics, Inc. Maleimide-functionalised platinum for use in the treatment of cancer
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN109171001A (zh) * 2018-09-14 2019-01-11 上海烟草集团有限责任公司 草酸钠在降低卷烟烟气中TSNAs释放量中的应用
IL294392A (en) * 2019-12-31 2022-08-01 Kinnate Biopharma Inc Treatment of cancer with cdk12/13 inhibitors
US20230339997A1 (en) * 2020-09-11 2023-10-26 Shanghai Haiju Biological Technology Co., Ltd. Class of platinum compounds for treating cancer, and method for preparation thereof
CN114163479B (zh) * 2020-09-11 2025-05-16 上海海聚生物科技有限公司 一类治疗癌症用的铂类化合物及其制备方法
CN114539320B (zh) * 2020-11-25 2026-01-27 北京大学 辐射激活的四价铂配合物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013130684A1 (en) * 2012-02-27 2013-09-06 Amunix Operating Inc. Xten-folate conjugate compositions and methods of making same
WO2015052516A1 (en) * 2013-10-08 2015-04-16 Atlas Genetics Limited Labelling compounds and their use in assays
CN106659706A (zh) * 2014-06-23 2017-05-10 普莱康治疗有限公司 铂化合物、组合物及其用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CH605550A5 (https=) 1972-06-08 1978-09-29 Research Corp
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS607934A (ja) 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソ−ムの製造方法
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3483949D1 (de) 1983-09-26 1991-02-21 Udo Dr Med Ehrenfeld Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
CS269719B1 (en) 1986-12-29 1990-05-14 Kiss Frantisek Platinum cytostatic
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
DE19636889A1 (de) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
AU756693B2 (en) 1997-09-29 2003-01-23 Novartis Ag Stabilized bioactive preparations and methods of use
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
AUPQ641100A0 (en) 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
DE10314780A1 (de) 2003-03-19 2004-09-30 Ktb Tumorforschungsgesellschaft Mbh Proteinbindende Derivate von Platinkomplexen mit Cyclobutan-1,1-dicarboxylatliganden
UA80872C2 (uk) 2003-03-31 2007-11-12 Пліва-Лахема А.С. Фармацевтична композиція, що містить як активну речовину платиновий комплекс, і спосіб її виготовлення
CZ296169B6 (cs) 2004-09-08 2006-01-11 Pliva - Lachema A. S. Farmaceutická kompozice pro rektální nebo vaginální podání, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
CZ2004964A3 (cs) 2004-09-14 2006-03-15 Pliva-Lachema A. S. Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
US20060205810A1 (en) 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
CZ300120B6 (cs) 2006-06-20 2009-02-11 Pliva - Lachema A. S. Farmaceutická kompozice pro injekcní podání
CZ300590B6 (cs) 2006-06-20 2009-06-24 Pliva - Lachema A. S. Farmaceutická kompozice pro injekcní podání
CZ300424B6 (cs) 2006-06-20 2009-05-13 Pliva - Lachema A. S. Farmaceutická kompozice pro perorální podání
RU2014124984A (ru) 2011-12-05 2016-01-27 Идженика Биотерапьютикс, Инк. Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы
EP3089745A4 (en) 2013-12-31 2017-05-17 Placon Therapeutics, Inc. Compounds, compositions, and methods for the treatment of cancers
EP3313392B1 (en) 2015-06-23 2020-09-16 Placon Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
US20180186823A1 (en) 2015-06-23 2018-07-05 Placon Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
EP3313527B1 (en) 2015-06-29 2021-02-24 Case Western Reserve University Anticancer drug-containing plant virus particles
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
WO2017214024A1 (en) 2016-06-06 2017-12-14 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
JP2019524706A (ja) 2016-07-08 2019-09-05 ジェネンテック， インコーポレイテッド Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用
WO2018026742A1 (en) 2016-08-01 2018-02-08 Askgene Pharma Inc. Novel antibody-albumin-drug conjugates (aadc) and methods for using them
CN108164512B (zh) 2017-12-27 2021-05-25 沈阳药科大学 一类具有生物粘附作用的马来酰亚胺型前药及其在口服药物传递中的应用
CN108187063B (zh) 2018-01-09 2020-09-08 沈阳药科大学 白蛋白结合型抗肿瘤药-马来酰亚胺分子前药

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013130684A1 (en) * 2012-02-27 2013-09-06 Amunix Operating Inc. Xten-folate conjugate compositions and methods of making same
WO2015052516A1 (en) * 2013-10-08 2015-04-16 Atlas Genetics Limited Labelling compounds and their use in assays
CN106659706A (zh) * 2014-06-23 2017-05-10 普莱康治疗有限公司 铂化合物、组合物及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery;Verena Pichler等，;《Chem. Commun.》;20131231;第49卷;全文 *

Also Published As

Publication number Publication date
MX2018006953A (es) 2019-05-16
MX377528B (es) 2025-03-10
CY1124529T1 (el) 2022-07-22
JP6867652B2 (ja) 2021-05-12
SMT202100709T1 (it) 2022-01-10
HRP20211466T1 (hr) 2021-12-24
WO2017097986A1 (en) 2017-06-15
US11572379B2 (en) 2023-02-07
DK3386997T3 (da) 2021-09-20
RS62412B1 (sr) 2021-10-29
PT3386997T (pt) 2021-11-04
LT3386997T (lt) 2021-12-10
SI3386997T1 (sl) 2021-11-30
AU2016367306B2 (en) 2021-04-22
US20180354979A1 (en) 2018-12-13
SG11201804885TA (en) 2018-07-30
PL3386997T3 (pl) 2021-12-13
EP3386997B1 (en) 2021-06-30
CN108368143A (zh) 2018-08-03
HUE056897T2 (hu) 2022-03-28
US10723748B2 (en) 2020-07-28
IL259864B (en) 2022-07-01
ES2898704T3 (es) 2022-03-08
JP2018538292A (ja) 2018-12-27
EP3386997A1 (en) 2018-10-17
CA3004630A1 (en) 2017-06-15
US20210002313A1 (en) 2021-01-07
AU2016367306A1 (en) 2018-06-14
IL259864A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
CN108368143B (zh) 用于癌症疗法的单马来酰亚胺官能化的铂化合物
KR101915452B1 (ko) 백금 화합물, 조성물 및 이의 용도
KR20200067132A (ko) 프로그램가능한 중합체성 약물
KR20200064059A (ko) 프로그램가능한 수지상 약물
JP2021506788A (ja) 生物学的に活性な化合物を含むイオン性ポリマー
KR20200083605A (ko) 프로그램가능한 중합체성 약물
JP5636091B2 (ja) 癌治療に用いるためのコンブレタスタチン類似体
CN114585625A (zh) 作为a2a/a2b抑制剂的三唑并嘧啶
JP7304128B2 (ja) 白金耐性の克服における使用のためのテキサフィリン－白金（ｉｖ）コンジュゲート及び組成物
JP7749542B2 (ja) 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート
CN114728934A (zh) 杂环衍生物、药物组合物和它们治疗或改善癌症的用途
JP7631329B2 (ja) リン脂質－フラバグリン抱合体及び標的化されたがん治療のためのリン脂質－フラバグリン抱合体の使用方法
CN112028891B (zh) 腺苷受体拮抗剂
TW202330015A (zh) 作為治療劑之肽微管蛋白抑制劑之肽結合物
CN117545479A (zh) Pi3k抑制剂、纳米制剂及其用途
CN116056698A (zh) 具有血脑屏障穿透能力的取代的1-(3,3-二氟哌啶-4-基)-咪唑并[4,5-c]喹啉-2-酮化合物
WO2025132831A1 (en) N-heteroaryl derivatives and uses thereof for treating cancer
WO2025022003A1 (en) Beta-peptides with cytotoxic activity on cancer cells
WO2024125662A1 (zh) 新型联芳环化合物作为免疫调节剂的制备和应用
EA047198B1 (ru) Конъюгаты фосфолипид-флаваглин и способы их применения для нацеленной противораковой терапии
HK40075720A (en) Phospholipid ether conjugates as cancer-targeting drug vehicles

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220201

CF01 Termination of patent right due to non-payment of annual fee